SG11201802956RA - Colloidal particles for use in medicine - Google Patents

Colloidal particles for use in medicine

Info

Publication number
SG11201802956RA
SG11201802956RA SG11201802956RA SG11201802956RA SG11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA
Authority
SG
Singapore
Prior art keywords
medicine
colloidal particles
colloidal
particles
Prior art date
Application number
SG11201802956RA
Other languages
English (en)
Inventor
William Henry
Richard Wolf-Garraway
John Mayo
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of SG11201802956RA publication Critical patent/SG11201802956RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201802956RA 2015-10-14 2016-10-14 Colloidal particles for use in medicine SG11201802956RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (1)

Publication Number Publication Date
SG11201802956RA true SG11201802956RA (en) 2018-05-30

Family

ID=55131025

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201802956RA SG11201802956RA (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
SG10202010711UA SG10202010711UA (en) 2015-10-14 2016-10-14 Colloidal Particles for Use in Medicine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202010711UA SG10202010711UA (en) 2015-10-14 2016-10-14 Colloidal Particles for Use in Medicine

Country Status (15)

Country Link
US (2) US20190192664A1 (ru)
EP (1) EP3362039A1 (ru)
JP (1) JP7160678B2 (ru)
KR (1) KR20180067616A (ru)
CN (1) CN108472246A (ru)
AU (1) AU2016336929B2 (ru)
BR (1) BR112018007399A2 (ru)
CA (1) CA3036111C (ru)
EA (1) EA201890703A1 (ru)
GB (1) GB201518172D0 (ru)
HK (1) HK1256814A1 (ru)
IL (1) IL258567A (ru)
MX (1) MX2018004445A (ru)
SG (2) SG11201802956RA (ru)
WO (1) WO2017064276A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7384994A (en) 1993-08-06 1995-02-28 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
MXPA00010241A (es) 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2379060A1 (en) 1999-07-14 2001-01-25 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CA2522179C (en) 2003-04-15 2012-02-14 Opperbas Holding B.V. Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
CA2613705A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
BRPI1010861A8 (pt) 2009-06-03 2023-01-24 Langton Iliffe George métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP6352950B2 (ja) * 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物

Also Published As

Publication number Publication date
SG10202010711UA (en) 2020-12-30
AU2016336929A1 (en) 2018-05-10
US20210093721A1 (en) 2021-04-01
AU2016336929B2 (en) 2022-09-29
GB201518172D0 (en) 2015-11-25
WO2017064276A1 (en) 2017-04-20
EP3362039A1 (en) 2018-08-22
EA201890703A1 (ru) 2018-11-30
CA3036111C (en) 2023-06-06
HK1256814A1 (zh) 2019-10-04
KR20180067616A (ko) 2018-06-20
IL258567A (en) 2018-05-31
MX2018004445A (es) 2018-08-14
JP7160678B2 (ja) 2022-10-25
US20190192664A1 (en) 2019-06-27
CA3036111A1 (en) 2017-04-20
CN108472246A (zh) 2018-08-31
BR112018007399A2 (pt) 2018-10-16
JP2018535952A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
GB2524085B (en) Exception handling in microprocessor systems
SG11201605896WA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
IL251630A0 (en) Combined therapy for use in cancer treatment
PL3046983T3 (pl) Wielowarstwowa cząstka ścierna
SG11201700968PA (en) Formulation comprising particles
GB201405614D0 (en) Particles
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
ZA201502203B (en) Nano particulate delivery system
IL250507B (en) Anti-ck8 antibodies for use in cancer treatment
GB201412841D0 (en) Particles
IL248424B (en) Neuroprotective substances and their uses
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
EP3177304A4 (en) Therapeutic nanoparticles for accumulation in the brain
HK1256814A1 (zh) 用於在藥物中使用的膠體顆粒
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
GB201701400D0 (en) Compound for use in medicine
SG11201606034WA (en) Device for delivering particles
GB201616880D0 (en) Compound for use in medicine
GB201516107D0 (en) Complexes and methods for their preparation
GB201701388D0 (en) Compound for use in medicine
EP3344661C0 (en) IRON POLYSACCHARIDE COMPLEXES AND METHOD FOR THE PRODUCTION THEREOF
GB201416493D0 (en) Polypeptides for use in therapy
GB201404831D0 (en) Animalistic studies in nature
GB201409978D0 (en) Novel compounds and their use in therapy